Table 4.

Predictive values of CMV-specific cellular assays in liver transplant recipients.

Test	AUC	Cohort	Time Point	Cut-Off	Sensitivity	Specificity
pp65 OI	0.744	All	M0	142	100%	46%
IE-1 Lo	0.762	All	M1	3.5	100%	59%
QuantiFERON	0.605	All	M1	32	100%	23%
pp65 Lo	0.700	D+/R-	M0	0.5	100%	40%
pp65 Lo	0.722	D+/R-	M1	0.5	100%	44%
pp65 OI	0.722	D+/R-	M1	3.5	100%	44%
QuantiFERON	0.667	D+/R-	M1	19	100%	33%

The value of CMV-specific cellular responses to predict the absence of CMV infection/reactivation was evaluated. For this analysis, the cut-off for CMV infection/reactivation was set at 500 copies of CMV-DNA/mL. It shows either data on all high- and intermediate-risk patients (All) or separately on high-risk patients [donor (D)+/recipient (R)− CMV-IgG serostatus prior to transplantation (D+/R−)]. CMV-specific ELISpot results were considered as spot forming units for CMV IE-1 and pp65 antigens, either at the end of antiviral prophylaxis (M0) or at month 1 (M1). Results of the QuantiFERON-CMV assays were given as IU/mL. The table considers the conditions with the greatest area under curve (AUC) for each assay, as determined by Receiver Operating Characteristic (ROC) curve analyses. A complete data set on the predictive value of all CMV-specific cellular assays is given as Supplementary Tables S2 and S3. OI—Oxford Immunotec (T-SPOT.CMV); Lo—Lophius Biosciences (T-Track CMV).